{"id":"https://openalex.org/W2583721613","doi":"https://doi.org/10.1182/blood.v108.11.2845.2845","title":"Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.","display_name":"Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.","publication_year":2006,"publication_date":"2006-11-16","ids":{"openalex":"https://openalex.org/W2583721613","doi":"https://doi.org/10.1182/blood.v108.11.2845.2845","mag":"2583721613"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v108.11.2845.2845","doi":"https://doi.org/10.1182/blood.v108.11.2845.2845","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2845.2845","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112026819","display_name":"Thomas S. Lin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas S. Lin","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066257150","display_name":"Mitch A. Phelps","orcid":"https://orcid.org/0000-0002-1615-5280","observed_orcids":["https://orcid.org/0000-0002-1615-5280"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mitch Phelps","raw_affiliation_strings":["College of Pharmacy, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002243266","display_name":"James T. Dalton","orcid":"https://orcid.org/0000-0002-3915-7326","observed_orcids":["https://orcid.org/0000-0002-3915-7326"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James T. Dalton","raw_affiliation_strings":["College of Pharmacy, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007739590","display_name":"Beth Fischer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Beth Fischer","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056946123","display_name":"Kristie A. Blum","orcid":"https://orcid.org/0000-0001-7363-9794","observed_orcids":["https://orcid.org/0000-0001-7363-9794","https://orcid.org/0000-0003-4229-2569"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristie A. Blum","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009630384","display_name":"Mollie E. Moran","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mollie E. Moran","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074900431","display_name":"Michelle Brooker-McEldowney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michelle B. McEldowney","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004511686","display_name":"Sara Broering","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Sara Broering","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069613777","display_name":"Alexander Dimitrios Colevas","orcid":"https://orcid.org/0000-0003-3849-4264","observed_orcids":["https://orcid.org/0000-0003-3849-4264"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Dimitrios Colevas","raw_affiliation_strings":["Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000921376","display_name":"John C. Byrd","orcid":"https://orcid.org/0000-0001-9830-0711","observed_orcids":["https://orcid.org/0000-0001-9830-0711"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John C. Byrd","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051619378","display_name":"Michael R. Grever","orcid":"https://orcid.org/0000-0002-1605-7875","observed_orcids":["https://orcid.org/0000-0002-1605-7875"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael R. Grever","raw_affiliation_strings":["Division of Hematology and Oncology, The Ohio State University, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology and Oncology, The Ohio State University, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5002243266","https://openalex.org/A5004511686","https://openalex.org/A5007739590","https://openalex.org/A5009630384","https://openalex.org/A5066257150","https://openalex.org/A5069613777","https://openalex.org/A5074900431"],"corresponding_institution_ids":["https://openalex.org/I4210140884","https://openalex.org/I52357470"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.5879,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.72323307,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"108","issue":"11","first_page":"2845","last_page":"2845"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/flavopiridol","display_name":"flavopiridol","score":0.9980000257492065},{"id":"https://openalex.org/keywords/relapsed-chronic-lymphocytic-leukemia","display_name":"relapsed chronic lymphocytic leukemia","score":0.9390000104904175},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9359999895095825},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7459999918937683},{"id":"https://openalex.org/keywords/continuous-intravenous-infusion","display_name":"continuous intravenous infusion","score":0.8529999852180481},{"id":"https://openalex.org/keywords/pharmacokinetic-modeling","display_name":"pharmacokinetic modeling","score":0.9139999747276306},{"id":"https://openalex.org/keywords/cmax","display_name":"Cmax","score":0.6050000190734863},{"id":"https://openalex.org/keywords/acute-tumor-lysis-syndrome","display_name":"acute tumor lysis syndrome","score":0.7929999828338623},{"id":"https://openalex.org/keywords/p53-independent-apoptosis","display_name":"p53-independent apoptosis","score":0.7699999809265137},{"id":"https://openalex.org/keywords/fludarabine-refractory-disease","display_name":"fludarabine-refractory disease","score":0.9179999828338623},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.367000013589859},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7329999804496765},{"id":"https://openalex.org/keywords/plasma-protein-binding","display_name":"plasma protein binding","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.8237529993057251},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.7872734069824219},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7210073471069336},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5448293089866638},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.529056191444397},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5066633820533752},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4188670516014099},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4161532521247864},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4113607108592987},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38321518898010254},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36585575342178345},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34048518538475037},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.14472973346710205},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.13253122568130493},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v108.11.2845.2845","doi":"https://doi.org/10.1182/blood.v108.11.2845.2845","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v108.11.2845.2845","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2561535000","https://openalex.org/W2591336637","https://openalex.org/W2595798036","https://openalex.org/W2258866093","https://openalex.org/W3016665764","https://openalex.org/W2595798132","https://openalex.org/W2564582633","https://openalex.org/W1967891134","https://openalex.org/W1563114076","https://openalex.org/W2045475939"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Flavopiridol":[2,519],"induces":[3],"p53-independent":[4],"apoptosis":[5,61],"in":[6,9,37,72,195,198,237,302,342,375,449,466,533],"CLL":[7,63,74,110],"cells":[8],"vitro.":[10],"Clinical":[11],"studies":[12,570],"using":[13,75],"24\u201372-hr":[14],"continuous":[15],"IV":[16,47],"infusion":[17],"(CIVI)":[18],"schedules":[19],"showed":[20],"little":[21],"activity,":[22],"due":[23,261],"to":[24,28,59,100,144,243,262,354,506,525,571],"increased":[25],"drug":[26,35],"binding":[27],"human":[29],"plasma":[30],"proteins":[31],"and":[32,203,210,286,318,325,407,437,454,512,561,576],"inadequate":[33],"free":[34],"concentrations":[36],"vivo.":[38],"Pharmacokinetic":[39],"(PK)":[40],"modeling":[41,214],"indicated":[42,215],"that":[43,216],"giving":[44],"flavopiridol":[45,83],"by":[46,51,84,88],"bolus":[48],"(IVB)":[49],"followed":[50,87],"4-hr":[52,89,219,552],"CIVI":[53,90,173,184,220,250,532,553],"would":[54,222],"achieve":[55],"the":[56,161,218,224,329,424,551,556,574],"necessary":[57],"concentration":[58],"induce":[60],"of":[62,128,147,229,234,294,298,309,333,356,380,399,415,446,462,491,510,579],"cells.":[64],"Methods:":[65],"We":[66],"conducted":[67],"a":[68],"phase":[69,568],"I":[70],"study":[71],"relapsed":[73,109],"this":[76,580],"PK-derived":[77],"dosing":[78],"schedule.":[79],"Patients":[80],"(pts)":[81],"received":[82,166],"30-min":[85],"IVB":[86,169,180,246,528],"weekly":[91],"for":[92,98,347],"4":[93,132,383,417,451,472,495],"doses,":[94],"every":[95],"6":[96,101],"weeks":[97],"up":[99],"cycles.":[102],"Results:":[103],"Fifty-eight":[104],"pts":[105,136,142,165,197,236,256,300,311,335,358,376,386,409,448,457,479,496,514,534],"(43":[106],"male)":[107],"with":[108,140,252,265,273,283,291,336,350,359,387,393,434,442,500,535,547],"(n=48)":[111],"or":[112,145,156,177,488],"small":[113],"lymphocytic":[114],"lymphoma":[115],"(n=10)":[116],"were":[117,207,257,322,410,480,504],"enrolled.":[118],"Median":[119,126,276],"age":[120],"was":[121,131,189,271,278,429],"60":[122],"years":[123],"(range,":[124,133,281,289,432,440],"38\u201384).":[125],"number":[127],"prior":[129],"therapies":[130],"1\u201314);":[134],"57":[135],"had":[137,150],"failed":[138],"fludarabine,":[139],"48":[141],"refractory":[143],"intolerant":[146],"fludarabine.":[148],"Pts":[149],"bulky":[151],"Rai":[152],"stage":[153],"I/II":[154],"(n=13)":[155],"III/IV":[157],"(n=45)":[158],"disease.":[159],"In":[160,476],"initial":[162],"2":[163,196,398,455,486,490],"cohorts,":[164],"30":[167,171,244,526],"mg/m2":[168,172,179,183,245,249,527,531],"+":[170,181,247,529],"(cohort":[174,185],"1,":[175,285,352,436],"n=20)":[176],"40":[178,182],"2,":[186],"n=3).":[187],"DLT":[188],"acute":[190],"tumor":[191],"lysis":[192],"syndrome":[193],"(TLS)":[194],"cohort":[199,238,303,382,416,450,471],"2.":[200,254,296,444],"The":[201,316],"0.5":[202,317],"4.5":[204,226,319,558],"hr":[205,227,320,559],"Cmax":[206,228,321,560],"2.08":[208],"\u03bcM":[209,324,327],"0.96":[211],"\u03bcM.":[212,231],"PK":[213,468],"increasing":[217],"dose":[221,241,259,266,274,284,292,314,351,368,394,397,411,435,443,481,489,501,523,548,554,581],"attain":[223],"target":[225,557],"1.5":[230],"Thus,":[232],"14":[233,310,408],"19":[235,299],"3":[239,304],"underwent":[240],"escalation":[242,369,395,502,582],"50":[248,530],"beginning":[251,483],"cycle":[253,295,400,485,492],"Five":[255,332],"not":[258,544],"escalated":[260,330,425,482,524],"severe":[263,348,545],"TLS":[264,349,546],"1.":[267,401,549],"Increased":[268],"anti-tumor":[269],"activity":[270,422,578],"observed":[272],"escalation.":[275,315],"LDH":[277,428],"344":[279],"U/L":[280,288,431,439],"147\u20135591)":[282],"858":[287],"215\u20132658)":[290],"1":[293,355,403,493],"Eleven":[297],"(58%)":[301],"achieved":[305,452],"PR,":[306,453],"including":[307],"10":[308],"(71%)":[312],"undergoing":[313],"1.95":[323],"1.54":[326],"at":[328,377,396,423,484],"dose.":[331],"8":[334],"WBC":[337,360,388,536],"\u2265":[338],"200":[339,362,390,538],"x":[340,363,391,539],"109/L":[341,540],"cohorts":[343],"1\u20133":[344],"required":[345,405,497],"hemodialysis":[346],"compared":[353],"34":[357],"<":[361,389,537],"109/L.":[364],"To":[365],"determine":[366],"if":[367,541],"could":[370],"be":[371,521],"safely":[372,522],"performed":[373],"earlier":[374],"lesser":[378],"risk":[379],"TLS,":[381],"enrolled":[384],"16":[385,447],"109/L,":[392],"One":[402],"pt":[404],"dialysis,":[406],"escalated.":[412],"Preliminary":[413],"results":[414],"indicate":[418],"modestly":[419],"greater":[420],"clinical":[421,565,577],"dose;":[426],"median":[427],"280":[430],"119\u20131616)":[433],"377":[438],"140\u20132547)":[441],"Six":[445],"additional":[456,508],"experienced":[458],">":[459],"50%":[460],"reduction":[461],"disease":[463],"without":[464],"improvement":[465],"counts.":[467],"data":[469],"from":[470],"is":[473,543],"being":[474],"analyzed.":[475],"total,":[477],"28":[478],"(n=14)":[487],"(n=14);":[494],"transient":[498],"dialysis":[499],"but":[503],"able":[505],"receive":[507],"doses":[509],"flavopiridol,":[511],"15":[513],"attained":[515],"PR":[516],"(54%).":[517],"Conclusions:":[518],"can":[520],"there":[542],"Increasing":[550],"achieves":[555],"translates":[562],"into":[563],"higher":[564],"activity.":[566],"Multi-center":[567],"II":[569],"further":[572],"investigate":[573],"safety":[575],"schedule":[583],"are":[584],"underway.":[585]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-10T00:00:00"}